JPS6260369B2 - - Google Patents
Info
- Publication number
- JPS6260369B2 JPS6260369B2 JP19236282A JP19236282A JPS6260369B2 JP S6260369 B2 JPS6260369 B2 JP S6260369B2 JP 19236282 A JP19236282 A JP 19236282A JP 19236282 A JP19236282 A JP 19236282A JP S6260369 B2 JPS6260369 B2 JP S6260369B2
- Authority
- JP
- Japan
- Prior art keywords
- blood
- neosugar
- sucrose
- weeks
- lipids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000002632 lipids Chemical class 0.000 claims description 21
- 235000000346 sugar Nutrition 0.000 claims description 11
- 229930091371 Fructose Natural products 0.000 claims description 9
- 239000005715 Fructose Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 8
- 150000002482 oligosaccharides Chemical class 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- 229920001542 oligosaccharide Polymers 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- 229930006000 Sucrose Natural products 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 239000005720 sucrose Substances 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 150000003626 triacylglycerols Chemical class 0.000 description 9
- 150000003904 phospholipids Chemical class 0.000 description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 208000004930 Fatty Liver Diseases 0.000 description 6
- 206010019708 Hepatic steatosis Diseases 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 208000010706 fatty liver disease Diseases 0.000 description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 5
- 241000700157 Rattus norvegicus Species 0.000 description 5
- 238000009534 blood test Methods 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000000185 sucrose group Chemical group 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 229960001052 streptozocin Drugs 0.000 description 4
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 108010042889 Inulosucrase Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000013116 obese mouse model Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19236282A JPS5982313A (ja) | 1982-11-04 | 1982-11-04 | 体内脂質減少剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19236282A JPS5982313A (ja) | 1982-11-04 | 1982-11-04 | 体内脂質減少剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5982313A JPS5982313A (ja) | 1984-05-12 |
| JPS6260369B2 true JPS6260369B2 (enExample) | 1987-12-16 |
Family
ID=16290014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP19236282A Granted JPS5982313A (ja) | 1982-11-04 | 1982-11-04 | 体内脂質減少剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5982313A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008120813A1 (ja) | 2007-04-03 | 2008-10-09 | Mitsubishi Tanabe Pharma Corporation | ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005247752A (ja) * | 2004-03-04 | 2005-09-15 | Hokuren Federation Of Agricult Coop:The | 血中コレステロール上昇抑制剤 |
| JP2012176907A (ja) * | 2011-02-25 | 2012-09-13 | Glico Dairy Products Co Ltd | フラクトオリゴ糖を有効成分とするミオシン軽鎖脱リン酸化促進剤、疾患の予防又は治療剤、及び飲食品 |
| JP7402628B2 (ja) * | 2019-07-19 | 2023-12-21 | 株式会社明治 | 組成物 |
-
1982
- 1982-11-04 JP JP19236282A patent/JPS5982313A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008120813A1 (ja) | 2007-04-03 | 2008-10-09 | Mitsubishi Tanabe Pharma Corporation | ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5982313A (ja) | 1984-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3548102B2 (ja) | 高血圧症予防・治療剤 | |
| US5919767A (en) | Use of pyruvate and anti-cortisol compounds in a method for enhancing physical endurance and athletic endurance in a mammal | |
| US5840705A (en) | α-glucosidase inhibitor, composition principally comprising sugar and containing the same, sweetener, food and feed | |
| EP0342956A2 (en) | Use of phytic acid or its salts for the treatment of hyperlipemia, obesity and obesity-related diseases | |
| JP2003522822A (ja) | 栄養性の改良されたイヌリン製品 | |
| WO1997047209A1 (en) | Lipid metabolism ameliorants | |
| JP5498521B2 (ja) | 放射線障害軽減剤 | |
| KR20150145262A (ko) | 에너지 소비의 촉진 및/또는 에너지 소비 기능 저하의 치료 및/또는 예방제, 또는 방법 | |
| WO2011077800A1 (ja) | 高脂血症改善剤、並びに、貧血改善組成物、尿酸値低下組成物及び飲食品 | |
| KR970011070B1 (ko) | 과콜레스테린혈증 치료용 혼합 조성물 | |
| JPH01294631A (ja) | 糖尿性疾患治療予防剤及び飲食、し好物 | |
| CZ2000324A3 (cs) | Použití chromu a farmaceutický prostředek | |
| JPWO2007114499A1 (ja) | 抗脂肪蓄積用組成物 | |
| JP2001072583A (ja) | 高脂血症の予防又は治療用組成物 | |
| JP7402826B2 (ja) | がん悪液質において用いる化合物 | |
| JPS6260369B2 (enExample) | ||
| JP5116072B2 (ja) | Ｄ−アロースの血糖上昇抑制効果の利用 | |
| JP4746281B2 (ja) | 生体内脂質調節剤 | |
| CN113712982A (zh) | 一种预防或治疗非酒精性脂肪肝、肥胖症的组合物及制备方法和应用 | |
| JP4115122B2 (ja) | 血糖値低下剤 | |
| JPH06504278A (ja) | ヒトの高い血糖値を低下させる方法 | |
| JP2021147394A (ja) | 牛樟芝の酒酔い解消及び／又はアルコール代謝増加に用いる用途 | |
| JP2006213684A (ja) | インスリン抵抗性改善に用いられる組成物及び健康用食品 | |
| DE60218165T2 (de) | Lipolyseförderer zur Reduzierung des Körpergewichts und medizinische Anwendung | |
| DE20206521U1 (de) | Zubereitung zur Appetitminderung, Sättigung und/oder Gewichtsreduktion |